

Form 603Corporations Act 2001
Section 671B**Notice of initial substantial holder**

To Company Name/Scheme Clinuvel Pharmaceuticals Limited

ACN/ARSN 089 644 119

1. Details of substantial holder (1)

Name Vanguard Group (The Vanguard Group, Inc. and its controlled entities including those listed in Annexure A)

ACN/ARSN (if applicable) N/A

The holder became a substantial holder on 10 August 2026

2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
Ordinary	2,523,018	2,523,018	5.003%

3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
Vanguard Group	Vanguard Group is the manager of various Mutual funds and accounts and in that capacity has the power to dispose of the shares. The other members of Vanguard Group have a relevant interest under section 608(3) of the Corporations Act.	Ordinary – 2,523,018

4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
Vanguard Group	Brown Brothers Harriman	Various funds and other accounts of Vanguard Group	Ordinary – 1,665
Vanguard Group	BNY Mellon	Various funds and other accounts of Vanguard Group	Ordinary – 234,683
Vanguard Group	JP Morgan Chase Bank, N.A.	Various funds and other accounts of Vanguard Group	Ordinary – 1,797,104
Vanguard Group	State Street Bank and Trust Company	Various funds and other accounts of Vanguard Group	Ordinary – 489,566

5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)	Class and number of securities
See Annexure A			

603 page 2/2 15 July 2001

6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
N/A	N/A

7. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Vanguard Group	P.O. Box 2600, V26 Valley Forge, PA 19482 USA

print name Shawn Acker capacity Compliance Manager

sign here  date 13 August 2026

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an Associate has a relevant interest in.
- (6) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (7) Include details of:
 - (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
- (9) Details of the consideration must include any and all benefits, moneys and other, that any person from whom a relevant interest has acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

Annexure A

To Company Clinuvel Pharmaceuticals Ltd.
ACN/ARSN 089 644 119

Substantial Holder Name Vanguard Group
ACN/ARSN N/A

Date of change	Person whose relevant interest changed	Nature of Change(6)	Consideration given in relation to change(7)	Class	Number of securities affected	Person's votes affected
10-Apr-2026	The Vanguard Group, Inc.	BUY	9.07	Ordinary	6,108	6,108
15-May-2026	The Vanguard Group, Inc.	BUY	9.47	Ordinary	215	215
03-Jun-2026	The Vanguard Group, Inc.	BUY	8.81	Ordinary	30,241	30,241
19-Jun-2026	The Vanguard Group, Inc.	BUY	10.26	Ordinary	32,668	32,668
07-Jul-2026	The Vanguard Group, Inc.	BUY	10.29	Ordinary	2,710	2,710
16-Jul-2026	The Vanguard Group, Inc.	BUY	10.12	Ordinary	14,653	14,653
05-Aug-2026	The Vanguard Group, Inc.	BUY	9.33	Ordinary	234	234
10-Aug-2026	The Vanguard Group, Inc.	BUY	9.63	Ordinary	1,588	1,588
10-Aug-2026	The Vanguard Group, Inc.	BUY	9.63	Ordinary	2,602	2,602
11-May-2026	Vanguard Investments Australia Ltd.	BUY	9.60	Ordinary	96	96
12-May-2026	Vanguard Investments Australia Ltd.	BUY	9.36	Ordinary	64	64
13-May-2026	Vanguard Investments Australia Ltd.	BUY	9.35	Ordinary	64	64
14-May-2026	Vanguard Investments Australia Ltd.	BUY	9.54	Ordinary	96	96
14-May-2026	Vanguard Investments Australia Ltd.	BUY	9.54	Ordinary	128	128
21-May-2026	Vanguard Investments Australia Ltd.	BUY	9.22	Ordinary	96	96
09-Jun-2026	Vanguard Investments Australia Ltd.	SELL	8.86	Ordinary	(160)	(160)
15-Jun-2026	Vanguard Investments Australia Ltd.	SELL	9.25	Ordinary	(96)	(96)
19-Jun-2026	Vanguard Investments Australia Ltd.	SELL	10.30	Ordinary	(93)	(93)
23-Jun-2026	Vanguard Investments Australia Ltd.	SELL	9.95	Ordinary	(186)	(186)
09-Jul-2026	Vanguard Investments Australia Ltd.	BUY	10.45	Ordinary	62	62
27-Jul-2026	Vanguard Investments Australia Ltd.	BUY	9.81	Ordinary	93	93
04-Aug-2026	Vanguard Investments Australia Ltd.	BUY	9.07	Ordinary	93	93

This is Annexure A of 1 page referred to in Form 603, Notice of initial substantial holder.

Signature:



Name: Shawn Acker

Capacity: Compliance Manager

Date: 13-Aug-2026